| Literature DB >> 25895507 |
Timothy J Shakespeare1, Diego Kaski2, Keir X X Yong3, Ross W Paterson3, Catherine F Slattery3, Natalie S Ryan3, Jonathan M Schott3, Sebastian J Crutch3.
Abstract
The clinico-neuroradiological syndrome posterior cortical atrophy is the cardinal 'visual dementia' and most common atypical Alzheimer's disease phenotype, offering insights into mechanisms underlying clinical heterogeneity, pathological propagation and basic visual phenomena (e.g. visual crowding). Given the extensive attention paid to patients' (higher order) perceptual function, it is surprising that there have been no systematic analyses of basic oculomotor function in this population. Here 20 patients with posterior cortical atrophy, 17 patients with typical Alzheimer's disease and 22 healthy controls completed tests of fixation, saccade (including fixation/target gap and overlap conditions) and smooth pursuit eye movements using an infrared pupil-tracking system. Participants underwent detailed neuropsychological and neurological examinations, with a proportion also undertaking brain imaging and analysis of molecular pathology. In contrast to informal clinical evaluations of oculomotor dysfunction frequency (previous studies: 38%, current clinical examination: 33%), detailed eyetracking investigations revealed eye movement abnormalities in 80% of patients with posterior cortical atrophy (compared to 17% typical Alzheimer's disease, 5% controls). The greatest differences between posterior cortical atrophy and typical Alzheimer's disease were seen in saccadic performance. Patients with posterior cortical atrophy made significantly shorter saccades especially for distant targets. They also exhibited a significant exacerbation of the normal gap/overlap effect, consistent with 'sticky fixation'. Time to reach saccadic targets was significantly associated with parietal and occipital cortical thickness measures. On fixation stability tasks, patients with typical Alzheimer's disease showed more square wave jerks whose frequency was associated with lower cerebellar grey matter volume, while patients with posterior cortical atrophy showed large saccadic intrusions whose frequency correlated significantly with generalized reductions in cortical thickness. Patients with both posterior cortical atrophy and typical Alzheimer's disease showed lower gain in smooth pursuit compared to controls. The current study establishes that eye movement abnormalities are near-ubiquitous in posterior cortical atrophy, and highlights multiple aspects of saccadic performance which distinguish posterior cortical atrophy from typical Alzheimer's disease. We suggest the posterior cortical atrophy oculomotor profile (e.g. exacerbation of the saccadic gap/overlap effect, preserved saccadic velocity) reflects weak input from degraded occipito-parietal spatial representations of stimulus location into a superior collicular spatial map for eye movement regulation. This may indicate greater impairment of identification of oculomotor targets rather than generation of oculomotor movements. The results highlight the critical role of spatial attention and object identification but also precise stimulus localization in explaining the complex real world perception deficits observed in posterior cortical atrophy and many other patients with dementia-related visual impairment.Entities:
Keywords: Alzheimer’s disease; agnosia; oculomotor; parietal lobe; visual function
Mesh:
Year: 2015 PMID: 25895507 PMCID: PMC4572483 DOI: 10.1093/brain/awv103
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Molecular pathology biomarkers in patients
| Diagnosis | PCA | PCA | PCA | PCA | PCA | PCA | PCA | PCA | PCA | PCA | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amyloid 18F imaging | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Positive | Positive | Positive | |
| CSF total tau (pg/ml) | 841 | 787 | 325 | 412 | 561 | 310 | 898 | N/A | N/A | N/A | |
| CSF Aβ1-42 (pg/ml) | 264 | 297 | 177 | 402 | 451 | 488 | 702 | N/A | N/A | N/A | |
| CSF tau: Aβ ratio | 3.19 | 2.65 | 1.84 | 1.02 | 1.24 | 0.64 | 1.28 | N/A | N/A | N/A | |
| Biomarker interpretation | + | + | + | + | + | +/− | − | + | + | + | |
| Amyloid 18F imaging | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| CSF total tau (pg/ml) | 828 | 843 | 1099 | 600 | 800 | 371 | 289 | 466 | >1200 | 2722 | 203 |
| CSF Aβ1-42 (pg/ml) | 125 | 129 | 195 | 125 | 297 | 245 | 280 | 298 | 452 | 528 | 511 |
| CSF tau: Aβ ratio | 6.62 | 6.53 | 5.64 | 4.80 | 2.69 | 1.51 | 1.03 | 1.56 | 2.65 | 5.16 | 0.40 |
| Biomarker interpretation | + | + | + | + | + | + | + | + | + | + | − |
+= Supportive of Alzheimer’s disease (either positive 18 F florbetapir amyloid scan or CSF amyloid-β1-42 < 550 pg/ml and tau:amyloid-β ratio > 1).
+/−= Compatible with Alzheimer’s disease (borderline level of CSF amyloidβ1-42 or ratio).
−= Atypical for Alzheimer’s disease.
Aβ = amyloid-β; tAD = typical Alzheimer’s disease; N/A = not available.
Mean and standard deviation performance metrics for PCA, typical Alzheimer’s disease and control groups on the fixation stability, saccade and sinusoidal pursuit tasks
aPatient group performance significantly worse than controls (bold text).
bPCA group performance significantly worse than typical Alzheimer’s disease group performance (cells highlighted).
cTypical Alzheimer’s disease group performance significantly different from PCA group performance (cells highlighted).
All marked (a,b,c) significant comparisons indicate P ≤ 0.05; see text for exact significance values.
Figure 1Representative traces from the fixation task in a healthy control, a patient with typical Alzheimer’s disease and a PCA patient. The upper plot (grey line) for each participant shows gaze position in the y (vertical) axis, the lower plot (black line) shows gaze position in the x (horizontal) axis. The location of the target stimulus is represented by thin black lines behind the traces. Gridlines show displacement of 1° of visual angle. The grey area in the plot for the PCA patient represents a blink (therefore x and y gaze coordinates are not available for this period). Positive values of gaze position indicate rightward gaze. The healthy control maintains steady fixation upon the target, whilst both patients show saccadic intrusions in the form of square-wave jerks. Additional large saccadic intrusions are evident in the PCA trace. tAD = typical Alzheimer’s disease.
Figure 2Representative traces from the saccade task for a healthy control, a patient with typical Alzheimer’s disease and a PCA patient in an ‘overlap’ trial. The upper plot (grey line) for each participant shows gaze position in the y (vertical) axis, the lower plot (black line) shows gaze position in the x (horizontal) axis. Gridlines show displacement of 1° of visual angle. Positive values of gaze position indicate rightward gaze. A central fixation point was present from the start of the trial until time point B (500 ms). The target appeared at 10° horizontally to the right of the central fixation point at time point A (300 ms) and remained present until the end of the trial. The healthy control and patients with typical Alzheimer’s disease make a single saccade towards the target. The PCA patient takes a long time to initiate their first saccade (in the incorrect direction), followed by a number of small saccades to reach the target location. tAD = typical Alzheimer’s disease.
Figure 3Interaction figure showing greater effect of overlap condition on time taken to reach the interest area in patients with PCA relative to patients with typical Alzheimer’s disease and controls. AD = Alzheimer’s disease.
Figure 4Example traces from the pursuit task for a healthy control, a patient with typical Alzheimer’s disease and a PCA patient. The figure shows a cycle towards the middle of the trial (seconds 4–8 from a trial of 10 s). Positive values of gaze position indicate rightward gaze. The upper plot (grey line) for each participant shows gaze position in the y (vertical) axis, the lower plot (black line) shows gaze position in the x (horizontal) axis. Target position is represented by a faint blue line. Gridlines show displacement of 1° of visual angle. tAD = typical Alzheimer’s disease.
P-values in the analysis of group differences in cortical thickness in each region of interest (upper section), and for correlations of oculomotor metrics with cortical thickness (combining both patient groups, but controls excluded; lower section)
| Table of | Parietal thickness | Frontal thickness | Temporal thickness | Occipital thickness | Central thickness | Cerebellar GM volume |
|---|---|---|---|---|---|---|
| Group differences | ||||||
| Con versus PCA | ||||||
| Con versus tAD | 0.072 | 0.205 | ||||
| PCA versus tAD | 0.790 | 0.837 | 0.341 | 0.634 | ||
| Correlations in combined patient group | ||||||
| SWJs in fixation | 0.624 | 0.152 | 0.980 | 0.667 | 0.500 | |
| Int. sac. in fix | 0.111 | 0.801 | ||||
| Saccade time to target | 0.939 | 0.357 | 0.170 | 0.623 | ||
| Saccade amplitude error | 0.336 | 0.703 | 0.600 | 0.057 | 0.478 | 0.993 |
| Velocity gain (pursuit) | 0.409 | 0.849 | 0.995 | 0.115 | 0.881 | 0.194 |
Bold highlight indicates significant effects.
aFrequency of intrusive saccades during fixation.
Con = control; GM = grey matter; tAD = typical Alzheimer’s disease; SWJ = square wave jerk.
Figure 5Mean cortical thickness and cerebellar grey matter volume for each patient group in each region of interest. Error bars indicate 95% confidence intervals. Asterisks indicate significant difference between patient groups. AD = Alzheimer’s disease; GM = grey matter.